NewAmsterdam reports data from Phase 3 BROADWAY trial, met primary endpoint

NewAmsterdam Pharma (NAMS) announced positive topline data from the Company’s Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with established atherosclerotic cardiovascular disease, ASCVD, and/or heterozygous familial hypercholesterolemia, HeFH, whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The primary endpoint was the least-squares mean of the percent change in LDL-C from baseline to day 84 for obicetrapib 10 mg compared to placebo, using imputation for missing data. The primary endpoint was achieved with statistical significance with an LDL-C reduction of 33%

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on NAMS:

• NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
• NewAmsterdam Pharma’s Promising Phase 3 Trial Results
• NewAmsterdam Pharma Reports Strong Q3 and Trial Progress
• Newamsterdam Pharma Faces Compliance Cost Surge as Emerging Growth Status Ends
• NewAmsterdam Pharma reports Q3 EPS (18c), consensus (50c)

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.